A randomised clinical trial investigating the effect of insulin glargine versus control in with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes
Studied treatment | insulin glargine (with a target fasting blood glucose level of ¡Ü95 mg per deciliter |
Control treatment | standard care |
HbA1c contrast | -0.3% |
Patients | with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes |
Group sizes | 6264 / 6273 |
primary prevention | |
history of cardiovascular |
Blindness | Inclusion period | ||
Follow-up duration | 6.2 years | Centers | |
Lost to FU | geographical localisation | ||
Primary endpoint | Design |
Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28 [PMID: 22686416] link to pdf add to Mendeley
ClinicalTrial.gov record NCT00069784
All trials of insulin glargine
Appears in following systematic reviews: